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Abstract
The roles that natural killer (NK) cells play in liver disease and transplantation
remain ill-defined. Reports on the matter are often contradictory, and the mechanisms elucidated are complex and dependent on the context of the model tested.
Moreover, NK cell attributes, such as receptor protein expression and function
differ among species, make study of primate or rodent transplant models challenging. Recent insights into NK function and NK-mediated therapy in the context of cancer therapy may prove applicable to transplantation. Of specific interest
are immune checkpoint molecules and the mechanisms by which they modulate
NK cells in the tumor micro-environment. In this review, we summarize NK cell
populations in the peripheral blood and liver, and we explore the data regarding
the expression and function of immune checkpoint molecules on NK cells. We
also hypothesize about the roles they could play in liver transplantation and discuss how they might be harnessed therapeutically in transplant sciences.

I N T RO DU CT ION

INTRODUCTION TO NATURAL
KILLER CELL BIOLOGY

Natural killer (NK) cells play a significant, yet often overlooked role in promoting graft tolerance during liver transplantation. Donor NK cells that reside within graft tissue
mediate tolerance through the direct killing of recipient
alloreactive T cells, which might otherwise promote graft
rejection. The potential role that enhanced donor NK cells
could have on promoting graft tolerance is largely unexplored, due to most established transplant therapies inhibiting immune function rather than enhancing it. Immune
checkpoint inhibitors are an emerging therapy developed
in the context of cancer. If these same drugs were instead
administered to graft NK cells, they might promote graft
tolerance through heightened NK-mediated killing of
alloreactive T cells.

NK cells are cytotoxic innate immune cells of the lymphoid
lineage.1,2 NK cells play a central role in the recognition
and killing of virus-infected cells3,4 and tumor cells.5–7
NK cells mediate their cytotoxic function through the
secretion of cytotoxic granules, which contain perforin,
granzymes, and other cytotoxic proteins.8 In contrast to
the lymphoid B and T cells, NK cells express germline-
encoded receptors to mediate their cytotoxic function. NK
cell cytotoxic function is governed by the net of activating
and inhibitory signals it receives through various receptors expressed on the cell surface.9,10
In human peripheral blood, NK cells have traditionally been divided into two major subpopulations marked
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by the expression level of the CD56 and CD16 surface
receptors. High expression of the CD56 surface receptor
(CD56brightCD16−) display strong cytokine secretion, but
weak cytotoxic activity with lower amounts of intracellular perforin and granzyme A and B.11–13 This subset is enriched in lymph nodes, and is less frequent in peripheral
blood.14 Conversely, CD56dimCD16+ NK cells have stronger cytotoxic activity and are the most abundant NK cell
detected in the peripheral blood.15 Although differentially
expressed, the precise molecular functions of CD56 on NK
cells remains elusive. It is not thought to be play a significant role in any major NK-mediated effector functions,
cytotoxic functions, or tolerance mechanisms. CD16 is a
marker of NK maturity and cytotoxic function; it is the
fragment crystallizable (Fc) gamma receptor and mediates
the NK cell’s antibody-dependent cellular cytotoxicity.
Recent investigations have revealed the presence of other
subpopulations of NK cells, including tissue-resident NK
cells (trNK) present in the uterus,16 lungs,17 and liver.13
Human NK cells have also been observed to differentiate into adaptive/memory-like phenotypes in response to
various stimuli, which have been described and reviewed
elsewhere.18–20

N K C E L L S M E DIAT E ACT IVAT ING
A ND I NH I B ITORY FU N CT ION
T H RO U G H GE R M LIN E -E N CODED
S URFAC E R ECE PTOR S
The interplay among activating and inhibitory NK cell
surface receptors is diverse and still being defined.21 Many
receptors belong to either the immunoglobulin-like superfamily of proteins or the C-type lectin superfamily. The
killer immunoglobulin-like receptor (KIR) genes are in the
leukocyte receptor complex (LRC) on chromosome 19,22
whereas the C-type lectin superfamily is located in the
natural killer gene complex (NKC) on chromosome 12.23
These member receptors mediate activating or inhibitory
phenotypes through conserved motifs known as immunoreceptor tyrosine-based inhibitory motifs (ITIMs) or immunoreceptor tyrosine-based activating motifs (ITAMs).21
The ITAMs are typically found within constitutively expressed transmembrane adaptor proteins, such as DAP-
12, the common Fc receptor gamma chain (FcRγ), and the
CD3-ζ chain.21 These are recruited to charged lysine residues within the transmembrane portion of activating receptors upon ligand binding. Examples of these activating
receptors include natural cytotoxicity receptors (NCRs),
most Fc receptors, natural killer group 2D (NKG2D),
and activating KIRs (aKIRs).21 On the other hand, ITIMs
are typically found within the cytoplasmic tails of the inhibitory receptors. Examples include inhibitory killer cell
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immunoglobulin-like proteins, NKG2A, and programmed
cell death protein 1 (PD-1).24
As stated above, most KIRs are members of the immunoglobulin superfamily on the LRC locus.25 These receptors mediate both activating and inhibitory function. The
inhibitory receptors within this family bind to major histocompatibility complex (MHC) class I molecules (such
as human leukocyte antigens [HLA]-A, -B and -C) and
thus provide the machinery required for NK education of
“self” versus “non-self” recognition.26,27 Activating KIRs
possess a much lower binding affinity for HLA ligands
and are expressed at a lower frequency compared to their
inhibitory counterparts.28 Some activating KIRs have been
suggested to play a role in protection against chronic viral
infection.29,30
The C-type lectin superfamily of NK cell receptors
includes the killer-cell lectin-like receptors (KLR).31 The
KLR are both activating and inhibitory receptors and are
located at the NKC locus on chromosome 12. KLRs can be
further divided into separate subfamilies based on ligand
interaction.31 KLRs that bind ligands with an MHC class
I-like fold include the CD94/NKG2 family of receptors.32
The activating receptor NKG2D is the most prominent
member of this subfamily, due to its central role in infection and tumor surveillance and clearing.33 Unlike NKG2D,
natural killer group 2A (NKG2A) and natural killer group
2C (NKG2C) dimerize with CD94 to form either the inhibitory CD94/NKG2A heterodimer or the activating CD94/
NKG2C heterodimer, both of which bind major histocompatibility complex, class I-E (HLA-E).34,35 Not unlike their
KIR counterparts, NKG2A contains an ITIM in its cytoplasmic tail, and NKG2C contains a charged residue in its
tail that recruits DAP-1236 (Figure 1).

HEPATIC TISSUE- R ESIDENT NK
C ELLS ARE PHENOTYPIC ALLY
AND FUNCTIONALLY DISTINCT
FROM PERIPHERAL NK C ELLS
NK cells make up ~10% of peripheral blood lymphocytes,
but account for 30–50% of intrahepatic lymphocytes.37,38
Hence, great effort has been put forth to understand
their role in liver disease and transplantation. Although
NK cells are the predominant hepatic lymphoid cell, two
separate and phenotypically distinct NK cell populations
within the liver have been identified. These include conventional NK cells traveling through the liver, and the hepatic trNK cells whose role in the liver microenvironment
have been the topic of numerous investigations.13
Conventional NK cells, which may coexist alongside
trNK cells in the liver, are phenotypically similar peripheral circulating NK cells. Hepatic conventional NK cells
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F I G U R E 1 A summary of critical NK cell receptors and checkpoint inhibitors, their cognate ligands, and intracellular signaling cascade.
In general, activating receptors will increase cell proliferation and cytokine production and function

are CD56dimCD16+, and functionally behave similar to
other peripheral CD56dim NK populations with increased
production of interferon-gamma and increased cytotoxicity.39 Originally, NK cells were thought to develop from
hematopoietic stem cells in the bone marrow. However,
later developmental stages are known to occur in secondary lymphoid tissues and other organs,40 suggesting local
development of certain NK populations and giving rise to
the distinctiveness of the hepatic NK cells.
Peng and colleagues first described specialized hepatic trNK cells in the murine liver.41 In mouse models,

conventional peripheral NK cells express the murine-
specific marker DX5, but do not express CD49a− (a marker
for a subunit of integrin alpha). In contrast, Peng and colleagues identified unique CD49a+DX5− cells which reside
in the hepatic sinusoids, but not in the efferent or afferent
hepatic blood supply.41 These CD49a+DX5− liver resident
NK cells are functionally different from their conventional counterpart as they exhibit unique memory-like effects against antigens. CD49a+DX5− NK cells, which had
previously been sensitized to antigen had a much more
robust antigen contact hypersensitivity response when
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challenged as compared to the CD49a−DX5+ conventional
NK cells.42 The authors suggested that this memory response may reflect NK cell priming in the liver.
Detection of this unique subset of trNK cells in murine models led to investigation for comparable human
liver trNK cells. Marquardt and colleagues identified
CD3−CD49a+CD56+ intrahepatic NK cells that could be
a human counterpart of the previously identified mouse
trNK cells.43 This human liver trNK cell subpopulation is
CD56bright and lacks CD16 expression. However, the CD49+
trNK also express high levels of mostly inhibitory KIR and
the activating receptor NKG2C, an expression pattern seen
in conventional CD56dim NK cells and after viral infection.44
Interestingly, high-resolution KIR phenotyping of the trNK
showed an oligoclonal expression pattern, suggesting a
clonal-like expansion of NK cells in this subset. Upon stimulation, these cells produced higher levels of proinflammatory cytokines, but lower levels of perforin with subsequent
poor degranulation and cytotoxicity compared to conventional CD56dim NK cells.43 This functional analysis is consistent with the murine hepatic trNK cells previously described
and may reflect a population of human NK cells with adaptive or memory-like capabilities.
Additional investigations have reported other phenotypic and functional descriptions of these human liver
trNK cells. Hudspeth and colleagues note the CD49a+ trNK
represents a fraction of the total trNK cell population.45
CD49a−CD56brightCD16− intrahepatic NK cells have also
been described that have high expression of surface C-X-C
motif chemokine receptor 6 (CXCR6), a protein that interacts with C-C motif chemokine ligand 16 (CCL16) expressed
in liver sinusoids.38,45,46 These CD49a−CD56bright NK cells
are a population of hepatic trNK cells retained within hepatic sinusoids. In addition to CXCR6, this population also
expresses the chemokine receptor C-C motif chemokine
receptor 5 (CCR5) and the tissue activation marker CD69,
surface markers not expressed on conventional CD56dim
NK cells.45 This subset also displays enhanced degranulation and efficient IFN-γ and tumor necrosis factor-alpha
(TNF-α) production, and they could be key to inflammatory
responses. However, they also express high levels of TNF-
related apoptosis-inducing ligand (TRAIL) and can mediate
the elimination of activated T cells, perhaps contributing to
the more tolerant liver environment.38,46

NAT UR A L K ILLE R CE LLS PLAY
VAR I A BL E ROLE S IN LIVE R
T R A NS P L A NT TOLE R AN CE AN D
REJ ECT I O N
The overall role of NK cells in liver transplantation remains
poorly understood. With reperfusion of the donor graft

HALMA et al.

upon transplantation, donor hepatic CD56brightCD16−
trNK and donor conventional NK cells are transferred to
the recipient. These cells are notable for the increased expression of the T-box transcription factor eomesodermin
(Eomes) in nearly half of the hepatic trNK cells, separating them from the uniformly Eomeslo peripheral blood
NK counterparts.47 More than 95% of trNK expressed the
tissue activation marker CD69, whereas samples of donor
peripheral blood showed only 4–7% of all NK cell populations expressed CD69.48 Of interest, donor Eomeshi hepatic
trNK seem to be long-lived, and can persist in an allograft
for 13 years. Donor hepatic Eomeslo NK cells can enter the
recipient’s circulation and are nearly undetectable more
than a few years after liver transplantation.47 These data
would suggest that CD56brightCD16−Eomeshi NK cells may
be the most “liver resident” NK cell population.
EomeshiCD56bright hepatic trNK cells express lower
levels of KIR, whereas CD94 (part of the inhibitory coreceptor complex with NKG2A) is expressed at high levels. Additionally, levels of perforin and granzyme B are
reduced, suggesting decreased cytotoxicity of this cell
population.47 On the other hand, the whole population
of hepatic donor CD56bright NK cells when studied by
Moroso and colleagues was more cytotoxic compared with
their peripheral counterparts.48 Together, this might suggest that the initial passenger CD56bright liver donor NK
cells could attack the recipient’s infiltrating lymphocytes
and prevent early graft rejection, but that longer-lived,
Eomeshi trNK from the donor would eventually contribute
to a more tolerogenic milieu.48
This more tolerogenic environment is well-recognized
within transplant medicine. An estimated 20% of liver
transplant recipients wean off immunosuppressive medications completely, developing “operational tolerance”
without development of graft rejection.49 The cellular
mechanisms which lead to operational tolerance are not
well understood; however, NK cells may contribute to its
development.50 Notably, de la Garza and colleagues found
a larger percentage of NK cells in peripheral blood samples in patients who developed operational tolerance as
compared to those who went on to develop acute rejection
following immunosuppression withdrawal.51 Relatedly, Li
and colleagues identified 13 genes which were highly expressed in operationally tolerant children and adults. All
13 genes were enriched in NK cell (CD56+) populations,
suggesting NK cells contributions to tolerance.52
Adding to these ideas, Pagano and colleagues found that
NK cells (based on a CD3−CD56+ cell population) made up
approximately one third of lymphocytes in the liver perfusate of deceased donors. The majority of these NK cells
expressed activating markers, including NKG2D.53 Of 46
donor liver perfusates analyzed, 11 recipients experienced
an episode of acute cellular rejection. The patients who
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experienced acute cellular rejection showed a significantly
lower percentage of NK cells in the liver perfusate (35%
NK cells for non-rejectors and 28% for rejectors). Having a
smaller donor liver NK cell population could translate as
decreased capability of donor NK cells to prevent recipient
immune response against the graft, thus increasing the likelihood of recipient rejection of the allograft.53
When considering NK cell activity in promoting graft
tolerance versus rejection, one must consider the role of
circulating recipient NK cells. Following graft transplant
and restoration of blood flow through the graft, recipient
NK cells are detected in the graft within hours.54 T cell mediated rejection is well accepted as the primary form of liver
graft rejection.55 The innate immune system—specifically
NK cells—may also participate in allograft rejection. Obara
and colleagues identified the rapid recruitment of recipient
NK cells to liver allograft in a murine model within 12 h
of transplantation.56 Upon graft infiltration, recipient NK
cells produced pro-inflammatory IFN-γ and helped recruit
T cells to the graft. When peripheral blood NK cells were
depleted, allografts had statistically significant decreases in
intrahepatic IFN-γ expression and prolonged survival.56
Understanding the role of circulating NK cells and graft
infiltration in humans has been more challenging with
conflicting reports between studies. Jamil and colleagues
found an increase in peripheral CD56bright NK cells after
transplant, but it is unclear if this increase was recipient
or donor derived.57 The CD56bright NK cells had decreased
expression of activating receptors NKp30 and NKp46. This
downregulation resulted in decreased NK functional capacities with impaired degranulation and IFN-γ production.57
If this same hypofunctional NK cell population trafficked
from the recipient into the donor graft, then they could play
a role in promoting graft tolerance. Alternatively, hypofunctional donor NK cells could perhaps allow increased activity
against the allograft by recipient immune cells.
Distinct from the findings of Jamil and colleagues,
Pham et al. noted a statistically significant decrease in the
number total NK cells and also the proportion of conventional CD56dim NK cells circulating in peripheral blood
post-transplantation.58 This decrease was transient and
may reflect the effects of immunosuppressive medications
versus trafficking of NK cells to the graft. In addition,
whereas the total number of NK cells circulating peripherally decreased in the immediate post-transplant period,
those that did remain in the periphery showed higher
levels of activating receptor NKp30 in both the CD56bright
and CD56dim populations, contrasting with the findings
described by Jamil and colleagues.57
Further in vivo studies delineating NK cell phenotypic
changes in response to the physiologic stress of transplantation, immunosuppressive medications, and the role of NK
cells as a bridge between the innate and adaptive immune

  

|

1095

systems at the time of transplant and during acute cellular
rejection are necessary. This will allow increased understanding of how NK cells might be harnessed to modulate
the allograft immune response (Figure 2).

IMMUNE CHEC KPOINT
MOLEC ULAR PATHWAYS ARE
IMPORTANT TO TRANSPLANT
TOLERANC E
Many immunosuppressive medications were developed
within the context of the “two signal” model of T cell activation. Signal one corresponds to T cell recognition (TCR/
HLA axis), and signal 2 to co-stimulatory pathways (including the prototypical CD28-CD80/86 T cell stimulatory
signaling pathway, among others).59–61 Overall, clinical
immunosuppressants used to treat liver and other solid
organ transplant recipients typically target signal one.62
However, important second signal pathways also include co-inhibitory pathways, meant to modulate unchecked immune activity from activated immune cells.
Co-inhibitory pathways that abrogate anti-graft immune
activity include cytotoxic T lymphocyte-associated protein-4 (CTLA-4; also known as CD152), PD-1 (also known
as CD279), and its ligands PD-L1 (B7-H1; CD274) and PD-
L2 (B7-DC; CD273).63,64 In the setting of persistent activation of the T cell, CTLA-4 and PD-1 interactions with their
ligands serve as inhibitory signals to regulate activation
and prevent disordered immune activity, including autoimmune disease and rejection.
The PD-1 “checkpoint” is key to maintaining peripheral tolerance.65 On the other hand, inhibiting this
pathway has become an exploitable target for increasing
immune activity.66 Such a strategy is useful in the typically tolerant tumor microenvironment where inhibition
can augment antitumor immune responses. In T-cells,
PD-1 inhibitory function is primarily mediated through
the phosphorylated immunoreceptor tyrosine-based
switch motif (ITSM), which recruits Src homology region
2 domain-containing protein tyrosine phopsphatase-2
(SHP-2). Although the exact mechanism with T-cells remains elusive, triggering of PD-1 shows inhibition of
phosphatidylinositol-3-kinase NF-kβ and Ras/MEK/Erk
pathways, resulting in impaired interleukin-2 (IL-2) production upon TCR/CD3 stimulation and cell cycle arrest.67
PD-1 signaling is also present in NK cells. PD-1 surface
expression is negligible in healthy CD56dim NK cells, however, may be induced. PD-1+ NK cells are most commonly
found in cytomegalovirus (CMV)-infected individuals, as
well as in several types of cancers.68 It is unclear to what
degree PD-1 is upregulated, or what downstream targets
it impacts, during the various mechanisms of NK cell
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F I G U R E 2 Donor (a) and recipient (b) NK cell activity in liver transplantation tolerance and rejection. In theory, targeted inhibition
of the PD-1 pathway in donor NK cells could enhance the killing of alloreactive recipient immune cells and limit rejection (a). However,
inhibiting immune checkpoints in recipient NK cells and other immune cell populations could augment the anti-graft response (b)

activation. Because T and NK cells share many signaling
molecules and coreceptors involved in cytotoxic activation
(the CD-3ζ chain present in both the TCR and CD16 activation complexes, for example), it stands to reason that
downstream targets of PD-1 activation overlap in NK and
T cells (Figure 3).

I M M U NE C HECK POIN T
I N H I BI TO RS M AY PROM OT E
T R A NS P L A NT R E J ECT ION
Inhibitors of the immune checkpoint have revolutionized
cancer immunotherapy by promoting an effector immune
cell environment, whereas the individuals own immune
system can become increasingly activated and destroy the
tumor. Therapeutic strategies known as immune checkpoint blockade (ICB) to target and block CTLA-4, PD-1 and
PD-L1 have been successful in multiple tumor types, such
as melanoma, non-small cell lung cancer, breast cancer,
and cervical cancer.69,70 Unfortunately, their utilization for
a patient with a solid organ transplant is often limited due
to concerns of potentiating transplant organ rejection. For

example, PD-1 activation plays a role in maintaining graft
tolerance after transplantation in part by preventing T cell
infiltration to the graft.71 Morita and colleagues found that
blocking the inhibitory PD-1 pathway in a murine transplanted liver led to severe acute rejection with organ necrosis due to profound T cell infiltration of the graft.64
Of interest, ICB is increasingly used in patients with
hepatocellular carcinoma (HCC). Patients with HCC can
be prime candidates for liver transplant, but graft and patient survival is affected by tumor recurrence. Because immune checkpoint inhibition is thought to promote graft
rejection, these drugs are not usually prescribed in the
context of liver graft recipients. Despite this, a small number of post-transplant patients with HCC have received
ICB to treat tumor recurrence, typically as a last resort.
Out of 19 cases of liver transplant recipients with advanced HCC who received ICB, 37% saw graft rejection.72
Another recent study has documented a single successful
treatment of disseminated HCC post-liver transplant with
nivolumab, a monoclonal antibody targeting PD-1.73
Clinical studies of checkpoint molecule inhibitors in
solid organ transplant recipients are largely limited to case
series reports and have shown mixed results. Fisher and
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F I G U R E 3 PD-1 signaling cascade in T cells. The PD-1
pathway is an important regulator of T cell activation, acting as a
“brake” to modulate the T cell response. PD-1 activation inhibits
signaling through both the nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) and extracellular signal-
regulated kinase (ERK) pathways. This in turn leads to reduced cell
proliferation and metabolism

colleagues completed a systematic review of 36 articles
(2 retrospective studies and 34 case reports/series) with a
total of 57 solid organ transplant recipients.74 In total, 37%
of patients experienced graft rejection and 14% died from
rejection when treated with a PD-1 or CTLA-4 inhibitor.74
When considering immune checkpoint inhibitor therapy
in the setting of liver transplant specifically, Munker and
De Toni reported that four out of 14 cases of liver transplant recipients who had received immune checkpoint inhibitors rejected the graft, with 75% mortality rate in those
who experienced rejection.75

E XP LO I TAT ION OF N K IMMU NE
C H EC K P O I N T M OLECU LE S
TO P RO M OT E TOLE R AN CE IN
T R A NS P L A NTAT ION
PD-1/PDL-1 blockade has garnered increased attention as
a target in cancer therapies,76–78 but little is known about
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exploiting activation of this pathway for therapeutic utility in organ transplant. PD-1 expression on hepatic T cells
has been well-documented in viral hepatitis, where, as a
marker of exhaustion, PD-1 leads to poor T cell adaptive
immune response and poor virus elimination.79,80 CD49a+
hepatic trNK cells may also be characterized by high expression of regulatory surface markers that include the
PD-1 ligand, PD-L1.81 These hepatic trNK cells were
shown to influence the adaptive immune response to viral
infection by inhibiting the antiviral T cell response via the
PD-1/PD-L1 pathway, thus inhibiting viral clearance and
contributing to the more tolerant microenvironment of
the liver.81
Hepatitis C viral infection has served as a model in better understanding the role of NK cells and immune checkpoints in viral clearance as well as progressive liver disease
post-transplant. Inhibition of viral clearance secondary to
reduced NK cell activity associated with increased PD-1
expression has been shown to contribute to the development of chronic hepatitis C viral infection.82 Collister and
colleagues further defined this role in noting that high
hepatitis C viral loads correlated with higher expression
of PD-1 on NK cells, finding that hepatitis C proteins were
able to induce NK cell exhaustion via the PD-1 pathway.83
Direct acting antiviral agents have revolutionized hepatitis C viral therapy by inhibiting viral replication, but the
mechanisms of immune modulation by these new antiviral agents may be nuanced. Szereday and colleagues
demonstrated that treatment with direct acting antiviral
agents resulted in decreased expression of immune checkpoint ligands, allowing for restoration of the previously
exhausted immune response.84
Beyond viral infections, the presence of CD49a+ trNK
cells in human HCC was associated with deteriorating disease conditions—including tumor thrombus and lack of a
tumor capsule—in addition to shorter overall and disease-
free survival.85 The presence of CD49+ cells was also associated with increased NK cell expression of the inhibitory
receptors NKG2A and PD-1, suggesting a tolerogenic NK
cell presence within liver tumor.85
These studies show that in the setting of viral infection
and cancer, activation of the PD-1/PD-L1 axis for T cells
and NK cells limits the adaptive immune response, the
primary regulator of graft rejection. In the setting of liver
transplant, Shi and colleagues demonstrated that PD-L1
is expressed on liver graft hepatocytes.86 During rejection,
PD-L1 is upregulated on lobular hepatocytes and sinusoids and portal cholangiocytes. In addition, graft infiltrating T cells were shown to have high expression of PD-1.
Blockade of the PD-1/PD-L1 pathway led to increased
intragraft T cell proliferation and further activation of
the immune system.86 Little is known about the role of
hepatic NK cells and the PD-1/PD-L1 axis in transplant;
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however, the current literature suggests that hepatic NK
cells are associated with increased graft tolerance. If these
same liver resident NK cells express PD-1 and PD-L1, and
blockade of the PD-1/PD-L1 axis increases T cell trafficking to the graft, then this suggests that intrahepatic PD-1
potentiation could limit T cell trafficking, increasing self-
tolerance and liver graft tolerance.

OTH E R NK IM MU N E CH ECK POINT
M O L EC U L E S, AN D POT E N T IAL
RO L E S I N L IVE R T R AN SPLAN T
TOL E RA NC E
In comparison to PD1/PDL1, much less is known about
the individual role other NK immune checkpoints play
during organ transplant. Recent investigation supports the
hypothesis that these inhibitory receptors may promote
NK self-tolerance in the setting of infection or tumor.87,88

T cell immunoreceptor with Ig and
ITIM domains
The T cell immunoreceptor with Ig and ITIM domains
(TIGIT)/nectin-like (Necl)/DNAX accessory molecule-1
(DNAM-1) axis plays a central role in NK cell maturation,
education, and tumor clearing.89 DNAM-1 is an activating
receptor expressed on NK cells and T cells. Upon binding nectin/Necl, the epithelial cell adhesion molecules
poliovirus receptor (PVR/CD155), and nectin-2 (CD112),
DNAM-1 triggers NK cell cytotoxic function, and facilitates the adhesion of NK cells to target cells bearing these
adhesion molecules.89 TIGIT binds PVR and nectin-2, and
inhibits NK cytotoxic function90 and cytokine secretion91
through an inhibitory signaling cascade mediated by the
ITIM domain in its cytoplasmic tail.
Expression of TIGIT in healthy human NK cells varies, with one study suggesting that TIGIT expression is
inversely correlated with NK cytokine production and cytotoxic potential, and that cytokine stimulation does not
significantly impact TIGIT expression level.92 The authors
of this study suggest that human NK cells naturally express high levels of TIGIT, which contrasts with results
obtained from mouse studies.88 Other recent studies have
shown that TIGIT might contribute to NK education in
an MHC-independent manner93 and inhibit cytokine production (namely IFN-γ) in mice.91 Studies in mice have
also revealed that blockade of TIGIT enhances NK effector
function in infection and cancer models.94,95 In the context
of immunotherapy, Roche’s anti-TIGIT tiragolumab has
recently been granted a US Food and Drug Administration
(FDA) Breakthrough Therapy designation when combined
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with atezolizumab (PD-L1 monoclonal antibody) in treating non-small cell lung cancer. A clinical trial evaluating
the safety and therapeutic potential of combining PD-1,
PVRIG, and TIGIT inhibition in treating solid advanced
tumors is currently underway (NCT04570839). Another
trial underway will compare therapeutic potential of the
already established elotuzumab (anti-SLAMF7 antibody)/
lenalidomide (thalidomide derivate that inhibits tumor
angiogenesis)/dexamethasone (corticoid steroid used to
reduce inflammation) multiple myeloma therapy versus
TIGIT blockade/lenalidomide/dexamethasone or lymphocyte activating 3 (LAG3) blockade/lenalidomide/dexamethasone in patients with relapsed multiple myeloma
(NCT04150965).
A study from 2014 suggests that during liver regeneration in mice, NK cells selectively upregulate TIGIT along
with PVR expression on hepatocytes.88 Using a murine
model, Bi and colleagues identified liver NK cells that
upregulate TIGIT in response to adenovirus infection.
Subsequently, TIGIT blockade resulted in increased NK
cell activation and liver injury, suggesting that TIGIT
expression by NK cells plays a key role in controlling
immune response to active infection and limiting NK mediated cellular destruction.88 The implications that this
might have for hepatic trNK cells in the transplanted graft
remain unclear, but the increased expression or stimulation of TIGIT in recipient infiltrating rtNK could be an
effective immune modulator.

T-cell immunoglobulin and mucin domain-
containing protein 3
T-cell immunoglobulin and mucin domain-containing
protein 3 (TIM-3) was first described as limiting IFN-γ secretion in cytotoxic and helper T-cells.96 Since then, it has
been reported in many other immune cells, including NK
cells.97 Ligands that have been identified for TIM-3 include
the soluble ligands galectin-9 and high mobility group box
1 (HMGB1), as well as the cell surface ligand ceacam-1.98
TIM-3 expression in human NK cells is a marker of NK
maturity that suppresses NK cytotoxic function when
cross-linked.97 Although named and described as a T cell
protein, TIM-3 is most highly transcribed in NK cells compared to other lymphocytes. TIM-3 is expressed in resting
and activated NK cells; expression may be enhanced via
cytokine stimulation or through CD16/Fc interactions.22
Induction of TIM-3 with its cognate ligand galectin-9 enhances IFN-γ production in vitro.97 Under specific culture
conditions, TIM-3 on NK cells may become downregulated
in response to cancer.97 TIM-3 expression on NK cells has
been associated with poor prognosis in various solid cancers99,100 and decreased expression was shown to correlate
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with better prognosis in patients with severe autoimmune
aplastic anemia.101 Clinical trials evaluating therapeutic
potential of TIM3 blockade on solid cancers alone or in
combination with LAG3 and PD-1 blockade are currently
underway (NCT02817633 and NCT03739710).
To better understand the role of immune checkpoint
molecules in the development of HCC, Tan and colleagues
bridged the gap between murine and human models by
identifying TIM-3+ NK cells in both species.87 CD49a+
murine liver trNK cells and CD49a− conventional NK
cells and the equivalent human CXCR6+ and CXCR6− NK
cells showed higher TIM-3 expression in tumor-infiltrated
cells as compared to normal tissue.87 This upregulation resulted in suppressed cytokine secretion and cytotoxic activity. Given that donor hepatic NK cells mediate tolerance
through cytokine secretion and cytotoxicity, one could
speculate that potentiation of the inhibitory checkpoint
pathway with upregulation of TIM-3 may result in decreased cytotoxicity/cytokine secretion of graft-infiltrating
recipient NK cells could also work to promote tolerance.

Lymphocyte activating 3 expression
Lymphocyte activating 3 (LAG3) expression may be induced
on a number of lymphocyte populations, including NK cells.
Liver and lymph node sinusoidal endothelial cell C-type lectin (LSECtin) serves as a ligand for LAG3 and is most prominently expressed in sinusoidal endothelial cells in the liver
and lymph nodes. In T-cells, LAG3 serves as a marker of
exhaustion in the context of cancer.102 Preliminary knockout studies in mice suggested that LAG3 might promote NK
cytotoxic function,103 however, this has not been observed
in any human in vitro models.104 The NK subgroups that
express LAG3 in response to stimulation tend to be mature,
cytokine secreting NK cells that have higher glycolytic activity when compared to LAG3- NK cells.105 A clinical trial
evaluating safety and immunotherapeutic potential of LAG3
blockade alone or with PD-1 blockade (NCT01968109) in
treating solid tumors is currently underway.

F UT U RE D I RECT ION S
Incorporating artificial intelligence and precision therapeutics into NK cell-based treatment strategies in transplantation will be paramount. As an example, performing
KIR-ligand mismatching prior to hematopoietic stem cell
transplantation has already become increasingly common, especially in treating acute myeloid leukemia.106 In
this application of precision medicine, NK-mediated graft-
versus-recipient phenotype is correlated with improved survivability and reduced risk of acute myeloblastic leukemia
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(AML) relapse. The NK cells derived from stem cell transplant are thought to display superior killing against the mismatched HLA ligands on the surface of cancer cells.107,108
Importantly, KIR-ligand mismatch does not seem to have
any significant impact on the onset of pathological graft-
versus-host disease or graft rejection. The impact that KIR-
ligand mismatch has during solid organ transplant has not
been investigated extensively, however, mismatched donor
NK cells could potentially display superior killing against
host alloreactive T cells that might otherwise mediate allograft rejection. In the context of liver transplant during liver
cancer, donor NK cells could display enhanced killing of
tumor cells, however, the persistence and potency of donor
hepatic NK cells within the graft environment have not
been fully characterized. Machine learning may aid in future efforts to improve precision medicine techniques during liver transplantation. Indeed, genetic predictive models
of tolerance during solid organ transplant have been established via machine learning in kidney109 and pancreatic islet
cell transplant.110 Potentially, these methodologies could be
used to decipher the KIR-HLA axis and find other positive
phenotype matches for liver transplantation.

INC REASING TRANSPLANT
ALLOGRAFT ACC EPTANC E BY
INCORPORATING CHEC KPOINT
PATHWAY TARGETS
In summary, recent insights have highlighted two distinct
liver NK cells populations—the conventional NK cell population which phenotypically and functionally are similar to circulating NK cells and the liver resident NK cells.
Liver transplantation results in a unique interface of these
two cell populations with transfer of donor liver trNK
cells to recipient and infiltration of recipient circulating
NK cells into the graft within hours of transplantation.
Following transplantation, donor liver resident NK cells
are found in an activated state with increased cytolytic
and cytotoxic activity, which helps mitigate infiltration of
recipient lymphocytes to the graft and thus allograft rejection. In contrast, recipient NK cells have been implicated
in acute graft rejection, although these mechanisms remain unclear.
Immune checkpoint pathways, such as PD-1/PDL-
1, act to inhibit immune dysregulation and have been
implicated as key mediators of preventing excess lymphocyte infiltration and acute cellular rejection of liver
grafts. Just as inhibition of the pathway has led to graft
rejection, exploitation through PD-1 promotors which
increase checkpoint molecule expression on recipient NK cells may further reduce graft infiltration and
thus improve graft tolerance. In contrast, inhibition of
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PD-1 and other checkpoint molecules leads to unmetered T cell activation with resultant hepatocellular
damage. Although the current checkpoint inhibition
immunotherapies that act broadly against cancer cells,
T cells, and NK cells often result in intrinsic liver damage, a targeted checkpoint inhibition for donor liver
resident NK cells could result in increased killing of
recipient immune cells, decreased graft infiltration, and
ultimately improved graft survival.
The identification of tissue resident, phenotypically
and functionally distinct NK cells provides a framework
for understanding the role of NK cells in organ transplant; however, much is still unknown with regard to
how NK cells promote tolerance versus induce rejection in liver transplantation. Future studies are needed
to better understand how phenotypic and functional
changes of NK cells affect graft outcomes. Immune
checkpoint molecules are present on tissue resident NK
cells and have been implicated in promoting graft tolerance. Additional studies should look to delineate the
mechanisms by which these inhibitory pathways regulate NK cell activation. Of particular interest would be
further development of immunotherapy with honing
of the checkpoint inhibitor pathway to the specific NK
cell phenotype to promote graft tolerance and expansion
of machine learning to advance our understanding of
these complex cellular interactions.
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